Inside the investigation: How LA County fraud was exposed

Investigators used Medicare billing data to flag an extreme outlier in Glendale. The case that followed became the largest Botox fraud scheme uncovered in the United States, and it played out inside LA County.

Data analytics flag the case

The DOJ Health Care Fraud Section’s analytics team noticed that one physician received far more Medicare payments for Botox than any other doctor in the country. Over four years the payments reached more than $24 million, six times the amount paid to the next highest providers.

That single statistic prompted a deeper look at Dr. Violetta Mailyan and her clinic, Healthy Way Medical Center. The numbers alone did not prove fraud, but they narrowed the field quickly and focused resources on one location.

Once the referral reached investigators, agents began matching billing records against travel logs, patient schedules, and clinic hours. The gap between claimed procedures and actual activity became impossible to ignore.

Clinic profile and billing pattern

Healthy Way Medical Center marketed itself primarily for cosmetic services. Medicare claims, however, listed thousands of Botox treatments for chronic migraines, a covered diagnosis when properly documented.

Records showed injections billed on dates when the doctor was traveling abroad or the clinic was closed. Some listed patients were later found to be incarcerated or out of state during the claimed visits.

The mismatch between cosmetic marketing and Medicare migraine claims gave agents a clear line of inquiry. They began collecting appointment books, travel records, and patient contact information to test the accuracy of each submission.

Subpoena triggers record tampering

A grand jury subpoena for patient files arrived in late 2025. Shortly afterward, agents discovered that certain charts had been altered to add migraine diagnoses that had not appeared in earlier versions.

Those changes formed the basis for additional obstruction charges. Prosecutors argued that the edits were an attempt to create a paper trail that never existed during the actual treatment period.

Altered records also contradicted pharmacy logs and appointment calendars already in government hands. The contradiction supplied direct evidence that the clinic had tried to conceal the original billing practices.

Financial scope of the scheme

Medicare ultimately paid about $33 million on the fraudulent claims. The total billed amount exceeded $45 million across several years of submissions.

Investigators traced proceeds to four residential properties valued above $7 million and a Cybertruck. Luxury purchases included high-end vacations and a $12,000 antique crossbow.

Asset forfeiture proceedings began immediately after indictment. The government moved to seize real estate and vehicles while the criminal case proceeded to trial.

Key evidence presented at trial

Prosecutors introduced travel itineraries showing the physician was in Mexico or Hawaii on dates when dozens of injections were billed. Calendars placed multiple patients out of state or in federal custody during claimed visits.

Clinic staff testified that cosmetic appointments were routinely logged under Medicare migraine codes. Internal messages and appointment software confirmed the dual bookkeeping system.

The combination of documentary evidence and witness statements eliminated any plausible medical justification for the volume of procedures claimed.

Conviction and sentencing timeline

On May 19, 2026, a federal jury convicted Dr. Mailyan on nine counts of wire fraud and three counts of obstructing a criminal investigation of healthcare offenses. Sentencing is scheduled for September 10, 2026.

The verdict marked the formal conclusion of the investigation that began with a single data flag. Prosecutors described the scheme as the largest Botox fraud case brought by federal authorities to date.

Defense attorneys have indicated they will seek a reduced sentence based on medical practice history and community ties, though the obstruction findings limit available arguments.

Local impact in Glendale and LA County

The clinic operated in a dense medical corridor where many practices serve both insured and cash-pay cosmetic clients. The case prompted neighboring offices to review their own Medicare documentation practices.

LA County health officials noted that legitimate migraine patients sometimes face longer wait times when clinics tighten internal controls after high-profile enforcement actions. No formal audit of area providers has been announced.

Local coverage in Glendale focused on the forfeited properties and what they revealed about the scale of the operation relative to the size of the medical practice.

Broader Medicare enforcement signal

The DOJ has used similar data analytics in other specialties, including pain management and dermatology. The Mailyan case demonstrated that Botox billing can be isolated and examined with the same tools.

Healthcare attorneys in Los Angeles report that clients are now requesting internal audits of high-volume injectable claims. The shift reflects concern that outlier detection will continue to drive new investigations.

Federal officials have stated that the same analytics platform will flag additional specialties where procedure volume appears inconsistent with patient population data.

Next steps after sentencing

Once sentencing concludes, remaining civil claims will determine how much of the $33 million Medicare payout can be recovered through judgments against the forfeited assets.

Any restitution order will be coordinated with the U.S. Attorney’s Office and the Centers for Medicare and Medicaid Services. The process typically extends several months beyond the criminal sentence.

LA County Fraud enforcement is expected to maintain its current pace as analytics teams continue scanning national billing data for comparable outliers in other injectable categories.

Case sets enforcement precedent

The conviction shows that data analytics can surface large-scale fraud even when the underlying service appears routine. It also illustrates how quickly obstruction charges can attach once records are altered after a subpoena.

Going forward, providers billing high volumes of any Medicare-covered injectable will face closer scrutiny of scheduling records and diagnosis documentation. The Glendale case supplies a concrete benchmark for what investigators now consider an actionable outlier.